MARK ROUNTREE: Open Payments
NPI 1265414775 · OCEAN SPRINGS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$662 in 27 payments from 8 companies in 2025. Trend: 2023 $694 · 2024 $645 · 2025 $662
Food & beverage: $662
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 8 | $177 |
| Novartis Pharmaceuticals Corporation | 4 | $108 |
| Genentech USA, Inc. | 4 | $93 |
| CSL Behring | 4 | $85 |
| BioCryst US Sales Co., LLC | 3 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $70 |
| Ionis Pharmaceuticals, Inc. | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: DUPIXENT, Xolair, ORLADEYO, CUVITRU, Haegarda, DAWNZERA, Rhapsido, Andembry.
Industry payments across MS — which companies pay providers there.
